BPA for palforzia base year with four one year option periods
Ended Awarded Last action
- Contract number
- 36E79721A0012
- Awardee
-
Aimmune Therapeutics, Inc. UEI E3ULPC7MFBK9
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 100% complete
- IDV ceiling
- $500,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
This single-award Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Aimmune Therapeutics, Inc. (UEI: E3ULPC7MFBK9) on April 15, 2021, with an ultimate completion date of April 14, 2026. The contract carries a ceiling value of $500,000 and operates under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule category. No set-aside designation was used in this award. The BPA encompasses a base year with four one-year option periods and incorporates 2026 Public Law pricing updates to ensure compliance with federal pricing requirements throughout the contract term.
The primary product procured under this agreement is Palforzia, an oral immunotherapy treatment indicated to reduce the severity of allergic reactions to peanuts in children and adolescents. This BPA facilitates streamlined acquisition of Palforzia for distribution across multiple Veterans Integrated Service Networks (VISNs) within the VA healthcare system, ensuring consistent access to this specialized pharmaceutical treatment for eligible veterans and their dependents. The single-award structure and consolidated vehicle consolidate procurement activities while enabling the VA to efficiently manage supply chain operations for this innovative biopharmaceutical product across its nationwide medical center network.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Show all 12
Quick answers
Who was awarded contract 36E79721A0012?
36E79721A0012 was awarded to Aimmune Therapeutics, Inc. by National Acquisition Center (Headquarters) on April 15, 2021.
How much is contract 36E79721A0012 worth?
36E79721A0012's own ceiling is $500,000.
Who can order from contract 36E79721A0012?
36E79721A0012 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79721A0012 under another contract?
Yes. 36E79721A0012 is a blanket purchase agreement under 36F79721D0150, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79721A0012 competed?
The extent of competition for 36E79721A0012 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV